New radioactive drug shows promise for Hard-to-Treat cancers
NCT ID NCT05723640
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 26 times
Summary
This early-stage study tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to see if the drug is safe and to find the best dose for future studies. Participants received up to 4 doses over two cycles, and researchers monitored side effects and how the drug moved through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, UNSPECIFIED, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National University Cancer Institute, Singapore National University Hospital, Singapore.
Singapore, 119077, Singapore
Conditions
Explore the condition pages connected to this study.